Summary

The Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma [RAINBOW; NCT01170663] is an international double-blind Phase 3 study of patients with metastatic gastric or gastroesophageal junction adenocarcinoma. This article presents the results from the planned region 1 subgroup analysis [Wilke H et al. Ann Oncol. 2014 (abstr O-0006)] consisting of Europe, Israel, the United States, and Australia.